Charles E. Sheedy - 31 Dec 2021 Form 5 Insider Report for Nuo Therapeutics, Inc. (AURX)

Role
10%+ Owner
Signature
/s/ Charles E. Sheedy
Issuer symbol
AURX
Transactions as of
31 Dec 2021
Net transactions value
+$286,323
Form type
5
Filing time
26 Apr 2022, 21:28:34 UTC
Previous filing
26 Apr 2022
Next filing
02 May 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURX Common Stock Exercise of in-the-money or at-the-money derivative security $286,323 +1,431,615 +16% $0.2000* 10,195,132 30 Dec 2021 Direct
holding AURX Common Stock 3,365 31 Dec 2021 Shares held in separate trusts for the benefit of children of the Reporting Person (673 shares in ea F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AURX Warrants to purchase Common Stock Other $0 +1,431,615 $0.000000 1,431,615 01 Dec 2021 Common Stock 1,431,615 $0.2000 Direct F2, F3
transaction AURX Warrants to purchase Common Stock Other $0 -1,431,615 -100% $0.000000* 0 01 Dec 2021 Common Stock 1,431,615 $0.4000 Direct F3, F4
transaction AURX Warrants to purchase Common Stock Exercise of in-the-money or at-the-money derivative security $0 -1,431,615 -100% $0.000000* 0 30 Dec 2021 Common Stock 1,431,615 $0.2000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
F2 Acquired in accordance with Warrant Modification Agreement dated as of 12/01/21
F3 The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price.
F4 Cancelled in accordance with Warrant Modification Agreement dated as of 12/01/21